This article details the documents provided to communicate with patients about medication risks as part of the CQC Navigator product.
Product Overview:
The CQC Navigator is a comprehensive toolset designed to assist GP surgeries in efficiently managing their compliance with Care Quality Commission (CQC) Key Performance Indicators (KPIs). It offers a structured and streamlined approach, allowing users to delegate tasks to the most suitable team members while maintaining a complete audit trail of all activities. The Navigator comprises lessons, searches, dedicated templates, and alerts to ensure practices remain ahead of CQC requirements. It also contains dedicated pre-written communications to use with your patients.
Letters available:
Hydrochlorothiazide Risk Letter
This letter highlights the risk of a small increased risk of non-melanoma skin cancer that may affect patients prescribed medications containing hydrochlorothiazide:

SGLT2 Risk Letter - Generic
This letter highlights the risk of SGLT2 inhibitors - specifically diabetic ketoacidosis and Fournier's gangrene. There are condition specific letters that can be used if you prefer - or this letter can be used for all patients on the medication:
Teratogenic drug risk
This letter highlights the risks of taking medication that is teratogenic and the need for highly effective contraception:
SGLT2 Risk Letter - CKD
This letter highlights the risk of SGLT2 inhibitors - specifically diabetic ketoacidosis and Fournier's gangrene. This is tailored to patients with CKD:
SGLT2 Risk Letter - Diabetes
This letter highlights the risk of SGLT2 inhibitors - specifically diabetic ketoacidosis and Fournier's gangrene. This is tailored to patients with Diabetes:
SGLT2 Risk Letter - Heart Failure
This letter highlights the risk of SGLT2 inhibitors - specifically diabetic ketoacidosis and Fournier's gangrene. This is tailored to patients with Heart Failure: